Verdence Capital Advisors LLC Increases Holdings in IQVIA Holdings Inc. $IQV

Verdence Capital Advisors LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 41.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,461 shares of the medical research company’s stock after purchasing an additional 9,539 shares during the period. Verdence Capital Advisors LLC’s holdings in IQVIA were worth $6,166,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC boosted its stake in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the last quarter. Empowered Funds LLC grew its holdings in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in IQVIA in the second quarter worth $514,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of IQVIA by 53.0% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 20,289 shares of the medical research company’s stock valued at $3,332,000 after buying an additional 7,030 shares during the period. Finally, NorthCrest Asset Manangement LLC bought a new position in shares of IQVIA during the 2nd quarter worth $206,000. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Down 1.3%

Shares of NYSE IQV opened at $238.03 on Tuesday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The business has a 50-day moving average of $227.80 and a 200-day moving average of $204.13. The firm has a market capitalization of $40.54 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 2.42 and a beta of 1.36. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Morgan Stanley boosted their target price on shares of IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Finally, Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $249.19.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.